Meridian Biopharmaceuticals has its focus on the development of innovative cancer immune
therapeutics, with emphasis on monoclonal antibody therapies and multi-epitope cancer vaccines.
Cancer is one of the leading causes of death in the developed countries and the second major
killer worldwide (besides cardiovascular disease). The statistical possibility to get the
diagnosis cancer in a humans life is 44% in men and 38% in women. In particular, metastatic
disease stages of cancer are not (or not sufficiently) amenable to standard cancer therapy
modalities such as surgery, radiotherapy or chemotherapy, and are responsible for the majority
of deaths of cancer patients.
The main focus of Meridian Biopharmaceuticals is the development of innovative products in
this therapeutic area of huge medical need. The transition of projects to higher development
stages, i.e. pre-clinical phase to clinical Phase I or Phase II, or even Phase III in
co-development with strategic partners is expected to add profound value.
Primary addressee for Meridians projects is the Big Pharma Industry which is known to
accomplish their pipelines more and more by inlicensing strategies.
Long time revenues for Meridian will be realized via royalties and milestone payments.